Multitasking E selectin

In patients with cancer, repeated rounds of chemotherapy exhaust the self-renewal capacity of hematopoietic stem cells, leading to prolonged bone marrow suppression, cytopenia and neutropenia. Now, researchers at the Mater Medical Research Institute, The University of Queensland and GlycoMimetics Inc. have mouse data showing that an antagonist of E selectin can alleviate this side effect of chemotherapy.¹

Based on the findings, the team will continue to work together to develop E selectin antagonists, but Mater Research and the biotech are driving different agendas on how to use those antagonists in oncology...